Ocular Therapeutix (OCUL) Enterprise Value (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Enterprise Value of -$598.6 million for Q2 2026, down 53.05% year-over-year from -$1.3 billion in Q2 2025, and up 10.21% on a QoQ basis from -$666.7 million in Q1 2026.
Ocular Therapeutix (OCUL) Enterprise Value (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Enterprise Value for 14 years, with the latest figure at -$598.6 million in Q2 2026.
- Enterprise Value for Q2 2026 came in at -$598.6 million, down 53.05% year-over-year; the trailing twelve-month figure through Jun 2026 was -$598.6 million (down 53.05% YoY), and the FY2025 annual result was -$737.1 million, down 87.98% from the prior year.
- Enterprise Value improved to -$598.6 million in Q2 2026, from -$666.7 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$66.6 million in Q2 2023 and troughed at -$737.1 million in Q4 2025.
- A 5-year average of -$322.5 million and a median of -$347.2 million in 2025 frame the typical range for Enterprise Value.
- The widest annual swing landed in 2023, when Enterprise Value jumped 50.49%; it then sank 590.16% in 2024.
- A 5-year view of Enterprise Value shows it stood at -$102.3 million in 2022, then sank by 91.55% to -$196.0 million in 2023, then plunged by 100.1% to -$392.1 million in 2024, then slumped by 87.98% to -$737.1 million in 2025, then rose by 18.78% to -$598.6 million in 2026.
- Per Business Quant data, the three most recent Enterprise Value figures were -$598.6 million in Q2 2026, -$666.7 million in Q1 2026, and -$737.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | -598.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -598.64 Mn |
| Mar 31, 2026 | -666.70 Mn |
| Dec 31, 2025 | -737.06 Mn |
| Sep 30, 2025 | -344.77 Mn |
| Jun 30, 2025 | -391.13 Mn |
| Mar 31, 2025 | -349.68 Mn |
| Dec 31, 2024 | -392.10 Mn |
| Sep 30, 2024 | -427.22 Mn |
| Jun 30, 2024 | -459.69 Mn |
| Mar 31, 2024 | -483.04 Mn |
| Dec 31, 2023 | -195.96 Mn |
| Sep 30, 2023 | -110.55 Mn |
| Jun 30, 2023 | -66.61 Mn |
| Mar 31, 2023 | -79.03 Mn |
| Dec 31, 2022 | -102.30 Mn |
| Sep 30, 2022 | -120.95 Mn |
| Jun 30, 2022 | -134.54 Mn |
| Mar 31, 2022 | -145.42 Mn |
| Dec 31, 2021 | -164.16 Mn |
| Sep 30, 2021 | -179.28 Mn |